Company intelligence / Profile preview

ALCEN

Ownership: Private
Development stage: Commercial

Overview

ALCEN supplies advanced medical machines for imaging/radiotherapy and develops radioactive tracer production systems. Its biotech subsidiary SkillCell has launched CE-marked diagnostic tests for insulin resistance and COVID.

Therapeutic areas: OtherEndocrinologyOncologyInfectious Diseases
Modalities: DeviceRadiopharmaceuticalDiagnostic deviceMedical machineBiologic technologyDiagnostic technology
Industry: Medical Imaging

Drug pipeline

4 assets

FLASHKNiFE

Clinical Trial

Indications: Cancer

3 more assets in the full pipeline.

Request access →

Partnerships

Collaborates with research centersTheryq partnered with Gustave Roussy on France’s “i-Démo” project

Beyond the preview

Go deeper on ALCEN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALCEN.

Explore the full profile